CWA Asset Management Group’s Royalty Pharma RPRX Stock Holding History

CWA Asset Management Group’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-326,087	Closed	-$10M	–	375
2023 Q2	$10M	Sell	326,087 -9,562	-3%	-$324K	0.69%	43
2023 Q1	$12.1M	Buy	335,649 +26,926	+9%	+$998K	0.9%	28
2022 Q4	$12.2M	Buy	308,723 +82,586	+37%	+$3.45M	0.99%	26
2022 Q3	$9.09M	Sell	226,137 -88,227	-28%	-$3.77M	0.88%	26
2022 Q2	$13.2M	Sell	314,364 -981	-0.3%	-$40.2K	1.24%	19
2022 Q1	$12.3M	Buy	315,345 +20,678	+7%	+$812K	0.94%	29
2021 Q4	$11.7M	Sell	294,667 -5,928	-2%	-$230K	0.87%	32
2021 Q3	$10.9M	Buy	300,595 +101,564	+51%	+$3.95M	0.86%	37
2021 Q2	$8.4M	Buy	199,031 +13,171	+7%	+$560K	0.68%	45
2021 Q1	$8.11M	Buy	185,860 +41,743	+29%	+$1.98M	0.74%	42
2020 Q4	$7.21M	Buy	+144,117	New	+$6.11M	0.76%	40

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CWA Asset Management Group's RPRX Position: Q3 2023 in Review

CWA Asset Management Group sold out of Royalty Pharma (RPRX) in Q3 2023, closing a stake of 326,087 shares — an estimated $10M sold.

CWA Asset Management Group first reported a position in RPRX in Q4 2020 and held it in 11 quarters. The position peaked at $13.2M in Q2 2022. 313 funds tracked by Wall St. Rank hold RPRX as of Q3 2023.

CWA Asset Management Group reported no remaining Royalty Pharma position as of Q3 2023 after selling out during the quarter.
CWA Asset Management Group sold 326,087 Royalty Pharma shares in Q3 2023, an estimated $10M.
CWA Asset Management Group first reported a position in Royalty Pharma in Q4 2020 and held it in 11 quarters.
CWA Asset Management Group's Royalty Pharma position peaked at $13.2M in Q2 2022.
313 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2023.

Based on CWA Asset Management Group's 13F filing for Q3 2023, filed 14 Nov 2023.